Get the Stockscreener App
27.40
1.22%
0.502
Tourmaline Bio Inc stock is traded at $27.40, with a volume of 34,885.
It is up +1.22% in the last 24 hours and up +1.86% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$26.90
Open:
$27.09
24h Volume:
34,885
Relative Volume:
0.18
Market Cap:
$700.52M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
-177.13
EPS:
-0.1547
Net Cash Flow:
$-19.23M
1W Performance:
+0.47%
1M Performance:
+1.86%
6M Performance:
+71.90%
1Y Performance:
+62.27%
1-Day Range:
$26.65
$27.68
1-Week Range:
$25.10
$27.68
52-Week Range:
$12.12
$48.31
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
AlphaCentric Advisors LLC Sells 69,500 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Tourmaline Bio shares get buy rating on IL-6 study optimism - Investing.com Canada
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DICE, Q - GuruFocus.com
The Best Curling Irons, Based On Several Months Of Testing - Forbes
Tourmaline Bio to Present at Upcoming Investor Conferences - The Manila Times
Short Interest in Tourmaline Bio, Inc. (NASDAQ:TRML) Declines By 20.0% - MarketBeat
Cantor Fitzgerald Predicts Tourmaline Bio FY2024 Earnings - Defense World
Tourmaline Bio, Inc. to Post FY2024 Earnings of ($2.85) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:TRML) - MarketBeat
Cantor Fitzgerald Upgrades Tourmaline Bio (NASDAQ:TRML) to “Strong-Buy” - Defense World
Tourmaline Bio (NASDAQ:TRML) Shares Up 6.3%Here's What Happened - MarketBeat
Tourmaline Bio Insiders Placed Bullish Bets Worth US$643.3k - Simply Wall St
Keros Therapeutics appoints new Chief Medical Officer - Investing.com
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer - GlobeNewswire
Cantor Fitzgerald Upgrades Tourmaline Bio (NASDAQ:TRML) to Strong-Buy - MarketBeat
Keros Therapeutics appoints new Chief Medical Officer By Investing.com - Investing.com Canada
Tourmaline Bio (NASDAQ:TRML) Shares Gap UpStill a Buy? - MarketBeat
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 - The Manila Times
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference - The Manila Times
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in ... - The Bakersfield Californian
TRMLTourmaline Bio, Inc. Latest Stock News & Market Updates - StockTitan
Investing in Tourmaline Bio Inc (TRML): What You Must Know - Knox Daily
Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting (NASDAQ:TRML) - Seeking Alpha
Cubist Systematic Strategies LLC Purchases Shares of 37,861 Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Shares Gap Down – Time to Sell? - Defense World
Tourmaline Bio (NASDAQ:TRML) Shares Gap DownTime to Sell? - MarketBeat
Guggenheim reiterates Buy on Tourmaline Bio shares, keeps price target By Investing.com - Investing.com UK
Tourmaline Bio to present research at Cardiometabolic Congress By Investing.com - Investing.com South Africa
Tourmaline Bio to present research at Cardiometabolic Congress - Investing.com
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress - The Manila Times
Tourmaline Bio announces CMO resignation By Investing.com - Investing.com South Africa
Tourmaline Bio announces CMO resignation - Investing.com India
Tourmaline Bio’s Chief Medical Officer Resigns Amicably - TipRanks
Tourmaline Bio, Inc. Announces Resignation of Yung Chyung as Chief Medical Officer,Effective October 31, 2024 - Marketscreener.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Marquette Asset Management LLC Raises Stake in Vera Bradley, Inc. (NASDAQ:VRA) - Defense World
Tourmaline Bio (NASDAQ:TRML) Stock Price Down 4.3%Should You Sell? - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Trading 6.4% HigherStill a Buy? - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Trading 6.4% Higher – What’s Next? - Defense World
Tourmaline Bio forms advisory board for heart drug By Investing.com - Investing.com South Africa
Tourmaline Bio forms Cardiovascular Scientific Advisory Board - TipRanks
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board - The Manila Times
Algert Global LLC Has $513,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
There is no way Tourmaline Bio Inc (TRML) can keep these numbers up - SETE News
Keeping an Eye on Tourmaline Bio Inc (TRML) After Insider Trading Activity - Knox Daily
Did Tourmaline Bio Inc (TRML) perform well in the last session? - US Post News
Keeping an Eye on PubMatic Inc (PUBM) After Insider Trading Activity - Knox Daily
Recent Insider Activity Suggests Potential Gains for Neogenomics Inc. (NEO) - Knox Daily
Crew Energy Inc. Announces Completion of Acquisition By Tourmaline Oil Corp. - Yahoo Finance
Graves’ Disease Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight - The Globe and Mail
Tourmaline Bio, Inc. (NASDAQ:TRML) Stock Position Boosted by Blue Owl Capital Holdings LP - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Rhumbline Advisers - MarketBeat
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tourmaline Bio Inc Stock (TRML) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | CEO |
Aug 16 '24 |
Buy |
13.79 |
5,221 |
71,998 |
5,221 |
| MCDADE MARK | Director |
Jan 29 '24 |
Buy |
32.50 |
100,000 |
3,250,000 |
448,431 |
| Kulkarni Sandeep Chidambar | CEO |
Nov 17 '23 |
Buy |
16.99 |
4,000 |
67,960 |
729,735 |
| Thiara Parvinder | Director |
Nov 17 '23 |
Buy |
17.31 |
1,000 |
17,310 |
83,782 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):